Mostrar el registro sencillo del ítem

dc.contributor.authorPallarés-Carratalá, Vicente
dc.contributor.authorbarrios, vivencio
dc.contributor.authorFierro González, David
dc.contributor.authorPolo Garcia, Jose
dc.contributor.authorCinza-Sanjurjo, Sergio
dc.date.accessioned2023-03-01T08:50:49Z
dc.date.available2023-03-01T08:50:49Z
dc.date.issued2023
dc.identifier.citationPallarés-Carratalá, V.; Barrios, V.; Fierro-González, D.; Polo-García, J.; Cinza-Sanjurjo, S. Cardiovascular Risk in Patients with Dyslipidemia and Their Degree of Control as Perceived by Primary Care Physicians in a Survey—TERESAOpinion Study. Int. J. Environ. Res. Public Health 2023, 20, 2388. https:// doi.org/10.3390/ijerph20032388ca_CA
dc.identifier.urihttp://hdl.handle.net/10234/201894
dc.description.abstractObjective: The aim of this study was to evaluate, through a survey, the opinion of primary care (PC) physicians on the magnitude of dyslipidemia and its degree of control in their clinical practice. Materials and methods: An ecological study was carried out, in which the physicians were invited to participate by means of an online letter. Data were collected at a single timepoint and were based only on the experience, knowledge, and routine clinical practice of the participating physician. Results: A total of 300 physicians answered the questionnaire and estimated the prevalence of dyslipidemia between 2% and 80%. They estimated that 23.5% of their patients were high-risk, 18.2% were very high-risk, and 14.4% had recurrent events in the last 2 years. The PC physicians considered that 61.5% of their patients achieved the targets set. The participants fixed the presence of side-effects to statins at 14%. The statin that was considered safest with regard to side-effects was rosuvastatin (69%). Conclusions: PC physicians in Spain perceive that the CVR of their patients is high. This, together with the overestimation of the degree of control of LDL-C, could justify the inertia in the treatment of lipids. Moreover, they perceive that one-sixth of the patients treated with statins have side-effects.ca_CA
dc.format.extent11 p.ca_CA
dc.format.mimetypeapplication/pdfca_CA
dc.language.isoengca_CA
dc.publisherMDPIca_CA
dc.relation.isPartOfInt. J. Environ. Res. Public Health 2023, 20(3).ca_CA
dc.rights© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).ca_CA
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/ca_CA
dc.subjectcardiovascular riskca_CA
dc.subjectdyslipidemiaca_CA
dc.subjectstatinsca_CA
dc.subjectside-effectsca_CA
dc.titleCardiovascular Risk in Patients with Dyslipidemia and Their Degree of Control as Perceived by Primary Care Physicians in a Survey—TERESA-Opinion Studyca_CA
dc.typeinfo:eu-repo/semantics/articleca_CA
dc.identifier.doihttps://doi.org/10.3390/ijerph20032388
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_CA
dc.relation.publisherVersionhttps://www.mdpi.com/1660-4601/20/3/2388ca_CA
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_CA
project.funder.nameFundacion SEMERGENca_CA


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

© 2023 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
Excepto si se señala otra cosa, la licencia del ítem se describe como: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).